Bridge Biotherapeutics
Monday, June 03, 2024
Multiple Therapeutics
Company Presentation Theater 3
Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations.
Company Website:
https://bridgebiorx.com/en/
Lead Product in Development:
BBT-877
Exchange
KOSDAQ
Ticker
288330
Company HQ City
Pangyo
Company HQ State
Gyeongi-do
Company HQ Country
Korea, Republic of
CEO/Top Company Official
James Lee
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())